Centre Hospital Region Metz Thionville
- Address
- lock Available on a paid plan
Neurology and Vascular Medicine
The clinical research at Centre Hospital Region Metz Thionville includes studies in nervous system diseases and cardiovascular diseases, focusing on conditions such as acute ischemic stroke and high-risk transient ischemic attack. These trials are designed to evaluate whether new treatment approaches can better prevent recurrent stroke and improve patient outcomes after a vascular event.
- Prevention of recurrent ischemic stroke
- Management of acute cerebrovascular risk
- Assessment of treatment benefit versus standard care
This work reflects a strong interest in improving care for patients at high risk of serious neurological and cardiovascular complications.
Hematology and Blood Cancers
A major part of the site’s research portfolio is centered on hemic and lymphatic diseases, especially acute myeloid leukemia and relapsed or refractory diffuse large B-cell lymphoma. These studies aim to test more effective therapies, deepen remission, and improve survival for patients with difficult-to-treat blood cancers.
- Improving remission rates in acute myeloid leukemia
- Comparing treatment strategies for relapsed lymphoma
- Evaluating overall survival and disease control
The hematology department at Centre Hospital Region Metz Thionville appears especially active in advancing treatment options for aggressive hematologic malignancies.
Oncology and Solid Tumors
The site also conducts research in neoplasms, including triple-negative breast cancer, colon carcinoma, and small bowel adenocarcinoma. These trials are exploring new cancer treatment combinations and strategies to improve survival, delay progression, and refine care for patients with advanced or high-risk disease.
- Testing new therapy combinations for breast cancer
- Evaluating treatment effectiveness in colorectal and small bowel cancers
- Studying ways to extend progression-free and overall survival
Research in this area highlights a broad commitment to better cancer control across several gastrointestinal and breast cancer settings.
Kidney and Blood Pressure Disorders
Clinical trials at the site also address digestive system and oral physiological phenomena and related chronic disease management, with an important focus on uncontrolled hypertension in people with moderate to severe chronic kidney disease. The goal is to evaluate treatment approaches that may slow kidney decline and reduce cardiovascular complications.
- Lowering blood pressure more effectively in chronic kidney disease
- Reducing progression to end-stage kidney disease
- Preventing cardiovascular events and mortality
This research supports better long-term management of patients facing both renal and vascular risk.
Brain Tumors and Diagnostic Research
The site is involved in studies on low grade glioma, combining nervous system diseases with diagnostic innovation. These trials are assessing whether advanced imaging can improve the characterization of suspicious brain lesions and support earlier, more accurate clinical decisions.
- Improving diagnosis of suspected gliomas
- Identifying more aggressive tumor features
- Supporting better treatment planning through imaging
This line of research emphasizes the value of better diagnostic tools in guiding care for patients with brain tumors.
Precision Oncology and Biomarker-Guided Care
Several trials at this hospital explore circulatory and respiratory physiological phenomena and digestive system diseases through biomarker-driven approaches. In colorectal cancer, for example, research is examining circulating tumor DNA to help identify patients who may benefit most from additional treatment after surgery.
- Using biomarkers to guide cancer treatment decisions
- Evaluating recurrence risk after surgery
- Improving personalization of oncology care
These studies show an interest in more tailored treatment strategies that match therapy to each patient’s disease biology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 17 therapeutic areas and 15 of 144 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 127 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 21 by active trials.
lock +20 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospital Region Metz Thionville
lock Showing 1 of 55 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 144 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Lenalidomide | 7 | Unknown | 2019-10-07 | 2025-07-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.